SCHEMBL113899

SCHEMBL113899

CSc1cc(-c2nc3ccccc3nc2Cl)nc(C)n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
TDP1 Q9NUW8 2/20 0.44
KDM4E B2RXH2 4/20 0.44
PKM P14618 2/20 0.44
KMT2A Q03164 1/20 0.34
TP53 P04637 4/20 0.34
POLB P06746 2/20 0.34
PDE4B Q07343 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
LMNA P02545 3/20 0.33
MAPT P10636 3/20 0.33
NQO2 P16083 2/20 0.33
GAA P10253 2/20 0.33
ALDH1A1 P00352 2/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PIK3CA P42336 1/20 0.32
PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750585 0.67 MAPT (0.46) KDM4EKMT2APOLBMAPTALDH1A1
SCHEMBL29451077 0.66 TDP1 (1.00) L3MBTL1TDP1KDM4EPKMKMT2A
SCHEMBL116696 0.66 TDP1 (1.00) L3MBTL1TDP1KDM4EPKMKMT2A
SCHEMBL115419 0.66 MAPT (0.39) L3MBTL1KMT2APOLBLMNAMAPT
SCHEMBL16077771 0.66 TDP1 (0.61) L3MBTL1TDP1KDM4EPKMKMT2A
SCHEMBL115490 0.65 MAPT (0.31) MAPT
SCHEMBL6351978 0.64 L3MBTL1 (0.58) L3MBTL1TDP1KDM4EPKMPDE4B
SCHEMBL20548570 0.64 L3MBTL1 (0.58) L3MBTL1TDP1KDM4EPKMPOLB
SCHEMBL21941944 0.64 METAP1 (0.57) L3MBTL1TDP1KDM4EPKMTP53
SCHEMBL15110244 0.64 L3MBTL1 (0.67) L3MBTL1TDP1KDM4EPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424859-B1 INHIBITORS OF PI3 KINASE AND / OR MTOR AMGEN INC (US) 2015-04-08 EP disclosed
US-8772480-B2 Inhibitors of PI3 kinase and/or mTOR AMGEN INC. (US) 2014-07-08 US disclosed
US-20130079303-A1 Inhibitors of PI3 Kinase and/or mTOR AMGEN INC. (US) 2013-03-28 US disclosed
US-8362241-B2 Inhibitors of PI3 kinase and/or mTOR AMGEN INC. (US) 2013-01-29 US disclosed
EP-2424859-A1 INHIBITORS OF PI3 KINASE AND / OR MTOR Amgen, Inc (US) 2012-03-07 EP disclosed
WO-2010126895-A1 INHIBITORS OF PI3 KINASE AND / OR MTOR AMGEN INC. (US) 2010-11-04 WO disclosed
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR AMGEN INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR MTOR, PIK3CA, PIK3CD L3MBTL1 4409/4885TDP1 2999/4885KDM4E 1916/4885
US-20130079303-A1 Inhibitors of PI3 Kinase and/or mTOR MTOR, PIK3CA, PIK3CD L3MBTL1 4409/4885TDP1 2999/4885KDM4E 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.